Omada Health (NASDAQ: OMDA) shares preliminary 2025 revenue ahead of J.P. Morgan talk

Rhea-AI Filing Summary

Omada Health, Inc. furnished an update on its recent performance by announcing preliminary, unaudited revenue for the fourth quarter and full fiscal year ended December 31, 2025. The company disclosed this information in connection with a public webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The preliminary figures are subject to completion of Omada’s year-end closing procedures and its annual independent audit and may be adjusted. The revenue details are contained in a press release attached as Exhibit 99.1, which is furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC reports.

0001611115false00016111152026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 12, 2026

Date of Report (date of earliest event reported)

Omada Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-42679						45-2355015
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
611 Gateway Blvd, Suite 120 South San Francisco, California									94080
(Address of Principal Executive Offices)									(Zip Code)

(888) 987-8337

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.001 par value per share			OMDA			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 2.02    Results of Operations and Financial Condition

On January 12, 2026, in advance of a public webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Omada Health, Inc. ("Omada") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025 and certain other information. The unaudited results are preliminary and subject to the completion of Omada’s final closing procedures and annual independent audit and are subject to adjustment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits.

Ex. Number			Ex. Description
99.1			Press Release
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OMADA HEALTH, INC.

Date: January 12, 2026

By:

/s/ Sean Duffy

Sean Duffy Chief Executive Officer

FAQ

What did Omada Health, Inc. (OMDA) disclose in this 8-K filing?

Omada Health, Inc. furnished a press release announcing its preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, along with certain related information.

Why did Omada Health (OMDA) release preliminary revenue information?

Omada released preliminary unaudited revenue in advance of a public webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Are Omada Health’s disclosed revenue figures final and audited?

No. The company states the results are preliminary, unaudited, and subject to completion of final closing procedures and its annual independent audit, and they may be adjusted.

How is the Omada Health (OMDA) press release treated under SEC rules?

The press release attached as Exhibit 99.1 is being furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings unless specifically referenced.

What exhibits are included with this Omada Health 8-K?

The filing lists Exhibit 99.1 as the press release and notes Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Omada Health (OMDA) 8-K report?

The report was signed on behalf of Omada Health, Inc. by Sean Duffy, the company’s Chief Executive Officer.